Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tari Ann King, M.D.

Co-Author

This page shows the publications co-authored by Tari King and Elizabeth Mittendorf.
Connection Strength

6.953
  1. Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery. J Clin Oncol. 2020 07 10; 38(20):2273-2280.
    View in: PubMed
    Score: 0.901
  2. Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come. Ann Surg Oncol. 2019 May; 26(5):1173-1175.
    View in: PubMed
    Score: 0.826
  3. ASO Visual Abstract: Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2021 Sep 08.
    View in: PubMed
    Score: 0.246
  4. Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2021 Sep 01.
    View in: PubMed
    Score: 0.246
  5. ASO Visual Abstract: Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. Ann Surg Oncol. 2021 Aug 08.
    View in: PubMed
    Score: 0.245
  6. Racial and Socioeconomic Disparities in Breast Cancer Outcomes within the AJCC Pathologic Prognostic Staging System. Ann Surg Oncol. 2021 Jul 30.
    View in: PubMed
    Score: 0.244
  7. Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 May 19.
    View in: PubMed
    Score: 0.241
  8. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy. Ann Surg Oncol. 2021 Nov; 28(12):7347-7355.
    View in: PubMed
    Score: 0.241
  9. Strategies to Optimize Axillary Surgery in Patients With Breast Cancer Receiving Neoadjuvant Endocrine Therapy. Oncology (Williston Park). 2020 Oct 09; 34(10):397-404.
    View in: PubMed
    Score: 0.231
  10. Multidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J Clin. 2020 11; 70(6):432-442.
    View in: PubMed
    Score: 0.231
  11. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
    View in: PubMed
    Score: 0.230
  12. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer. Ann Surg Oncol. 2021 Mar; 28(3):1358-1367.
    View in: PubMed
    Score: 0.229
  13. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. NPJ Breast Cancer. 2020 Aug 13; 6(1):35.
    View in: PubMed
    Score: 0.229
  14. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. NPJ Breast Cancer. 2020; 6:35.
    View in: PubMed
    Score: 0.229
  15. Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. J Am Coll Surg. 2020 10; 231(4):434-447.e2.
    View in: PubMed
    Score: 0.228
  16. Patient preferences for locoregional therapy in early-stage breast cancer. Breast Cancer Res Treat. 2020 Sep; 183(2):291-309.
    View in: PubMed
    Score: 0.228
  17. The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. Ann Surg Oncol. 2020 Sep; 27(9):3393-3401.
    View in: PubMed
    Score: 0.227
  18. Staging for Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Utility of Incorporating Biologic Factors. Ann Surg Oncol. 2020 Feb; 27(2):359-366.
    View in: PubMed
    Score: 0.217
  19. Patterns of Axillary Management in Stages 2 and 3 Hormone Receptor-Positive Breast Cancer by Initial Treatment Approach. Ann Surg Oncol. 2019 Dec; 26(13):4326-4336.
    View in: PubMed
    Score: 0.215
  20. Prognostic Significance of Residual Axillary Nodal Micrometastases and Isolated Tumor Cells After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2019 Oct; 26(11):3502-3509.
    View in: PubMed
    Score: 0.211
  21. Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). JNCI Cancer Spectr. 2018 Nov; 2(4):pky063.
    View in: PubMed
    Score: 0.204
  22. Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence. Surg Clin North Am. 2018 Aug; 98(4):687-702.
    View in: PubMed
    Score: 0.196
  23. Trends and controversies in multidisciplinary care of the patient with breast cancer. Curr Probl Surg. 2016 Dec; 53(12):559-595.
    View in: PubMed
    Score: 0.177
  24. The 2013 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: MRI in breast cancer: where are we now? Ann Surg Oncol. 2014 Jan; 21(1):28-36.
    View in: PubMed
    Score: 0.143
  25. Neoadjuvant Endocrine Therapy in Clinical Practice: A Review. JAMA Oncol. 2021 Sep 09.
    View in: PubMed
    Score: 0.062
  26. Clinico-pathologic predictors of patterns of residual disease following neoadjuvant chemotherapy for breast cancer. Mod Pathol. 2021 05; 34(5):875-882.
    View in: PubMed
    Score: 0.058
  27. Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):227-241.
    View in: PubMed
    Score: 0.056
  28. Comparative Analysis of Proposed Strategies for Incorporating Biologic Factors into Breast Cancer Staging. Ann Surg Oncol. 2020 Jul; 27(7):2229-2237.
    View in: PubMed
    Score: 0.055
  29. Incorporating Patient-Reported Outcome Measures into Breast Surgical Oncology: Advancing Toward Value-Based Care. Oncologist. 2020 05; 25(5):384-390.
    View in: PubMed
    Score: 0.055
  30. Surgical Management of the Axilla in Clinically Node-Positive Patients Receiving Neoadjuvant Chemotherapy: A National Cancer Database Analysis. Ann Surg Oncol. 2019 Oct; 26(11):3517-3525.
    View in: PubMed
    Score: 0.053
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.